NASDAQ: OTLK
Outlook Therapeutics Inc Stock Ownership - Who owns Outlook Therapeutics?

Insider buying vs selling

Have Outlook Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Ghiath M. SukhtianDirector2025-05-274,285,714$1.40
$6.00MBuy

1 of 1

OTLK insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when OTLK insiders and whales buy or sell their stock.

OTLK Shareholders

What type of owners hold Outlook Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Ghiath M. Sukhtian100.64%83,599,563$20.73MInsider
Faisal Ghiath Sukhtian67.28%55,884,786$13.86MInsider
Biolexis Pte Ltd30.63%25,443,159$6.31MInsider
Arun Kumar Pillai27.67%22,982,529$5.70MInsider
Pankaj Mohan9.97%8,285,115$2.05MInsider
Schonfeld Strategic Advisors LLC2.94%2,441,355$605.46kInstitution
Syntone Ventures LLC2.05%1,705,438$422.95kInsider
Vanguard Group Inc1.76%1,465,167$363.36kInstitution
Jeff Evanson0.97%808,459$200.50kInsider
Terry Dagnon0.79%653,058$161.96kInsider

1 of 3

OTLK vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
OTLK3.29%96.71%Net Buying
SER1.07%98.93%Net BuyingNet Buying
QNCX32.84%67.16%Net Buying
XCUR0.23%99.77%Net SellingNet Selling
KTTA50.00%50.00%Net Buying

Outlook Therapeutics Stock Ownership FAQ

Who owns Outlook Therapeutics?

Outlook Therapeutics (NASDAQ: OTLK) is owned by 8.21% institutional shareholders, 241.76% Outlook Therapeutics insiders, and 0.00% retail investors. Ghiath M. Sukhtian is the largest individual Outlook Therapeutics shareholder, owning 83.60M shares representing 100.64% of the company. Ghiath M. Sukhtian's Outlook Therapeutics shares are currently valued at $20.23M.

If you're new to stock investing, here's how to buy Outlook Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.